Leukaemia Foundation supports myeloma biomarker breakthrough
Friday, 16 March 2018
Research released by QIMR Berghofer Medical Research Institute today identifying the IL-18 molecule as an important biomarker for myeloma is being hailed an important step by the Leukaemia Foundation.
Myeloma is a blood cancer which affects the body’s plasma cells – the cells that produce antibodies. Myeloma
Leukaemia Foundation Chairman Joins Shave Crew
Wednesday, 21 February 2018
“Be bold, go bald!”
That’s the call to action from Leukaemia Foundation Chairman, Beverley Mirolo OAM, as she prepares to lose her locks in this year’s 20th World’s Greatest Shave.
Beverley’s team is strong, with daughter Fiona, granddaughter Stephanie
Haematologist swims oceans to make a difference
Monday, 22 January 2018
Haematologist Orly Lavee will be taking on a 2km ocean swim and 10km coastal run in the Sydney Morning Herald 2018 Sun Run Cole Classic from February 3-4 to help raise awareness and funds for the Leukaemia Foundation.
One of the oldest sporting events in Australia, the
Growing concern as blood cancer rates continue to rise
Tuesday, 16 January 2018
The Leukaemia Foundation’s CEO Bill Petch is reminding the nation the number of Australians dying from blood cancer is now DOUBLE those losing their life to melanoma 1, as registrations for the 20th anniversary of World’s Greatest Shave open today.
Ibrutinib now cheaper for patients
Monday, 09 October 2017
The Leukaemia Foundation welcomes the Federal Government’s announcement that the cancer medicine, IMBRUVICA® (ibrutinib) will be added to Pharmaceutical Benefits Scheme (PBS) from 1 December 2017.
Bill Petch, CEO at the Leukaemia Foundation said this announcement is an important step forward for people living with Read More
The latest on CAR T-cell therapy research
Wednesday, 28 June 2017
A clinical trial will test advancements in chimeric antigen receptor (CAR) T-cell therapy developed in Australia and funded by the Leukaemia Foundation*.
The clinical trial opened in Sydney in August 2017 for people with relapsed B-cell leukaemias and lymphomas, following TGA and ethics approvals.
World-first blood test could provide more effective, less invasive blood cancer treatments
Tuesday, 20 June 2017
A world-first “liquid biopsy” could soon offer you direct access to a simple blood test to help in the monitoring and management of your blood cancer treatment.
The blood test promises a new era of less invasive, more precise and effective management of your blood cancer, in
15-year Holden partnership celebrated
Thursday, 15 June 2017
A brand new Astra, Trailblazer and Trax were unveiled at the recent joint celebration acknowledging Holden’s 15 years of support for the Leukaemia Foundation’s Patient Transport Program in Victoria, bringing their fleet support from 17 vehicles to 20.
Many of our amazing volunteer drivers, supporters of the
Australians living with MPN step closer to accessing Pegasys treatment
Thursday, 08 June 2017
The drug interferon alfa-2a (Pegasys®) was finally listed on the agenda of the Pharmaceutical Benefits Advisory Committee (PBAC) meeting on March 8 and many Australians are awaiting the results of the discussion.
For Nathalie Cook, who was diagnosed with MPN in 2008, this achievement was especially exciting
Life-saving Hodgkin lymphoma treatment now available on PBS
Sunday, 02 April 2017
Participants of two Leukaemia Foundation surveys have helped inform the Pharmaceutical Benefits Advisory Committee of the benefits of brentuximab vedotin, a potentially life-saving treatment for Australians diagnosed with a form of Hodgkin lymphoma*, supporting its listing on the PBS from April 1.
The PBS listing of brentuximab